OakChart

Aldeyra Therapeutics Inc

ALDXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 12:59 PM ET

0.6255-0.0036 (-0.57%)
2026-11-11 19:00 CET
Market cap
37.97 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-19.13 USD m
Free cash flow, TTM
-19.15 USD m
EPS diluted, TTM
-0.32
P/E
-
Compare

Price

ALDX against its 20, 50 and 200-day averages
2050200miss
1.002.003.004.004.1M8.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALDXclose 0.6320-day 0.6550-day 1.00200-day 2.100.63

89.4% under the 52-week high of 5.93 on 30 Jan 2026. 52-week low 0.53 on 2 Nov 2026. Last 15 sessions, 39.5% high to low

Profile

ALDX
52-week range, 2% of the way up
0.535.93

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Employees8
IPOMay 02, 2014
Beta1.27
ATR, 14d0.08
Rel volume1.19
Short float5.44%
Insider own3.70%
Inst own62.05%

Snapshot

6 groups

Valuation

Index-
Market Cap37.75M
Enterprise Value-2.76M
Income-19.13M
Sales0.00M
Book/sh0.58
Cash/sh0.68
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOMay 02, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.07
P/C0.92
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.37
Current Ratio5.37
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.32
EPS next Y-0.27
EPS next Q-0.08
EPS this Y43.57%
EPS next Y15.82%
EPS next 5Y38.54%
EPS past 3/5Y19.04% 12.61%
Sales past 3/5Y- -
EPS Y/Y TTM56.04%
Sales Y/Y TTM-
EPS Q/Q51.21%
Sales Q/Q-
EarningsJul 31
EPS/Sales Surpr.-16.13% -

Ownership

Insider Own3.70%
Insider Trans12.60%
Inst Own62.05%
Inst Trans-5.45%
ROA-31.57%
ROE-45.29%
ROIC-53.88%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.62%
SMA50-37.65%
SMA200-70.27%
Trades-

Technical

Shs Outstand60.36M
Shs Float58.13M
Short Float5.44%
Short Ratio2.77
Short Interest3.16M
52W High5.93 -89.45%
52W Low0.53 18.67%
Volatility14.96% 12.77%
ATR (14)0.08
RSI (14)34.76
Beta1.27
Rel Volume1.19
Avg Volume1.14M
Volume758,626

Performance

Perf Week-3.38%
Perf Month-30.48%
Perf Quarter-56.56%
Perf Half Y-63.21%
Perf YTD-87.92%
Perf Year-88.04%
Perf 3Y-72.63%
Perf 5Y-93.02%
Perf 10Y-90.11%
Recom1.40
Target Price6.60
Prev Close0.63
Price0.63
Change %-0.57%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Mar 18, 2026DowngradeHH.C. WainwrightBuy → Neutral$2+219.7%
Apr 03, 2024UpgradeOOppenheimerPerform → Outperform$10+1,498.7%
Apr 02, 2024ResumedHH.C. WainwrightBuy$10+1,498.7%
Apr 27, 2022ResumedHH.C. WainwrightBuy$15+2,298.1%
Feb 08, 2021InitiatedHH.C. WainwrightBuy$26+4,056.7%
Dec 16, 2020InitiatedBBerenbergBuy$32+5,015.9%
Oct 30, 2020InitiatedJJefferiesBuy$24+3,736.9%
Oct 16, 2020InitiatedBBTIG ResearchBuy$29+4,536.3%
Sep 22, 2020InitiatedAAlliance Global PartnersBuy$32+5,015.9%
May 12, 2020InitiatedOOppenheimerOutperform$12+1,818.5%

Peers

Mkt cap
TickerCompanyMkt cap
OKYOOKYO Pharma Limited74.00M
BLCOBausch + Lomb Corp7.61B
KALAKala Bio Inc3.28M
LENZLENZ Therapeutics Inc132.28M
TARSTarsus Pharmaceuticals Inc3.77B
OCULOcular Therapeutix Inc1.45B
IRDOpus Genetics Inc366.48M
EYPTEyePoint Inc32.01M
KPRXKiora Pharmaceuticals Inc6.31M
HROWHarrow Inc1.10B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Brady Todd CPresident and CEOJun 03 '26Buy1.67250,000418,4501,721,298Jun 05 04:19 PM
DOUGLAS RICHARDDirectorMar 19 '26Buy1.4070,00098,000195,000Mar 20 04:17 PM
Alfieri MichaelPrincipal Financial OfficerMar 18 '26Buy1.425,0007,1007,500Mar 19 05:29 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter (InvestorsHub) +13.79%
  • Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease (Business Wire)
  • Aldeyra Therapeutics to Host Regulatory Update Webcast (Business Wire)
  • Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors (Business Wire)
  • Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (Business Wire)
  • Loading…
  • Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
  • Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALDX (Business Wire)
  • Aspens fresh Parkinsons data; Aldeyra tanks following FDA rejection (BioPharma Dive) +14.52%
  • FDA issues CRL to Aldeyras reproxalap drug application (Hospital Management)
  • Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile) -70.69%
  • Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire)
  • Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
  • Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference (MarketBeat) +5.37%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-31-0.090-0.078-0.0900.000.004
2026Q12026-04-30-0.060-0.098-0.0570.000.004
2025Q42026-03-12-0.116-0.140-0.1070.000.006
2025Q32025-11-13-0.130-0.141-0.1280.000.006
2025Q22025-08-08-0.161-0.240-0.1630.000.006
2025Q12025-05-01-0.170-0.280-0.1660.00-1.007
2024Q42025-03-06-0.269-0.263-0.2650.000.006
2024Q32024-11-07-0.251-0.247-0.2540.000.008
2024Q22024-08-02-0.273-0.206-0.2840.000.008
2024Q12024-05-02-0.135-0.111-0.1360.001.208
2023Q42024-03-07-0.080-0.111-0.0800.003.006
2023Q32023-11-09-0.140-0.196-0.1390.000.007
2023Q22023-09-11-0.151-0.172-0.1530.000.007
2023Q12023-05-04-0.270-0.290-0.2660.000.007
2022Q42023-03-09-0.220-0.313-0.2200.000.008
2022Q32022-11-10-0.250-0.344-0.2490.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.240-2.484-2.2440.000.00
2020FY-1.110-1.095-1.1060.000.00
2021FY-1.070-1.100-1.0690.000.00
2022FY-1.060-1.155-1.0620.000.00
2023FY-0.640-0.667-0.6370.002.57
2024FY-0.940-0.931-0.9390.000.00
2025FY-0.560-0.595-0.5600.000.00
2026FY--0.316--0.00
2027FY--0.266--7.11
2028FY--0.130--21.51
2029FY-0.150--53.36
2030FY-0.270--74.44

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-282000.000.000.00
2026Q3S2026-08-142010.000.000.00
2026Q3S2026-08-082002.500.005.00
2026Q3S2026-07-312012.500.005.00
2026Q3S2026-06-122012.500.005.00
2026Q3S2026-05-25301-0.59-6.775.00
2026Q3S2026-04-30300-0.26-6.775.00
2026Q3S2026-03-17300-0.26-6.775.00
2026Q3S2026-03-12200-0.88-6.775.00
2026Q3S2026-03-04200-0.88-6.775.00
2026Q3S2025-11-141005.005.005.00
2026Q3R2026-11-09510-0.08-0.10-0.06
2026Q3R2026-10-28500-0.09-0.11-0.08
2026Q3R2026-10-20501-0.09-0.11-0.08

Estimate history

EPS, annual-1.4-1.794-2.244-1.106-1.069-1.062-0.637-0.939-0.564-0.3173
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.254-0.265-0.166-0.163-0.128-0.107-0.057-0.09-0.062
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual19.13826.24428.65738.66758.08158.5659.19659.64860.16360.357
Period201720182019202020212022202320242025MRQ
Shares, quarterly59.5559.64860.04660.04660.16360.16360.32160.32160.357
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.360.250.250.260.260.260.060.100.07
Gross Profit-0.36-0.25-0.25-0.26-0.26-0.26-0.06-0.10-0.07
Selling, General and Administrative Excl. Other19.8435.0159.8742.5362.4255.9634.6156.4139.63
Research and Development12.0425.6648.2229.4647.3144.9424.6844.3529.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-20.20-35.27-60.12-42.79-62.68-56.22-34.67-56.51-39.70
Interest Expense0.941.911.932.071.691.741.900.600.15
Unusual Expense0.000.000.000.000.000.001.756.57-
Net Income Before Taxes-19.13-33.85-55.85-37.54-62.02-57.78-38.03-62.14-38.89
Income Taxes0.000.000.000.000.000.00-0.48-1.310.00
Consolidated Net Income-19.13-33.85-55.85-37.54-62.02-57.78-37.55-60.83-38.89
Net Income From Continuing Operations-19.13-33.85-55.85-37.54-62.02-57.78-37.55-60.83-38.89
Net Income-19.13-33.85-55.85-37.54-62.02-57.78-37.55-60.83-38.89
EPS (Recurring)-0.32-0.56-0.94-0.64-1.06-1.07-1.07-2.07-1.79
EPS (Basic, Before Extraordinaries)-0.32-0.56-0.94-0.64-1.06-1.07-1.11-2.24-1.79
EPS (Diluted)-0.32-0.56-0.94-0.64-1.06-1.07-1.11-2.24-1.79
EBITDA-19.84-35.01-59.87-42.53-62.42-55.96-34.61-56.41-39.63
Non-Operating Income (Expense)2.023.326.197.322.350.190.291.540.95
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.866.097.975.758.297.115.174.304.14
Shares Outstanding60.3660.1659.6559.2058.5658.0838.6728.6626.24
Market Capitalization37.9737.97297.15206.47407.58232.37266.31162.41217.83

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.150.070.070.070.060.060.060.06
Gross Profit-0.15-0.07-0.07-0.07-0.06-0.06-0.06-0.06
Selling, General and Administrative Excl. Other3.985.783.486.607.9410.1110.3716.51
Research and Development1.843.482.414.305.438.517.4214.63
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.14-5.85-3.55-6.67-8.00-10.17-10.43-16.58
Interest Expense0.000.000.470.480.480.470.480.47
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.76-5.45-3.45-6.46-7.69-9.77-9.93-15.81
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.76-5.45-3.45-6.46-7.69-9.77-9.93-15.81
Net Income From Continuing Operations-3.76-5.45-3.45-6.46-7.69-9.77-9.93-15.81
Net Income-3.76-5.45-3.45-6.46-7.69-9.77-9.93-15.81
EPS (Recurring)-0.06-0.09-0.06-0.11-0.13-0.16-0.17-0.27
EPS (Basic, Before Extraordinaries)-0.06-0.09-0.06-0.11-0.13-0.16-0.17-0.27
EPS (Diluted)-0.06-0.09-0.06-0.11-0.13-0.16-0.17-0.27
EBITDA-3.98-5.78-3.48-6.60-7.94-10.11-10.37-16.51
Non-Operating Income (Expense)0.370.400.560.680.790.870.981.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.111.64-0.991.092.580.202.221.26
Shares Outstanding60.3660.3260.3260.1660.1660.0560.0559.65
Market Capitalization37.97128.48101.71311.64312.65229.40343.32297.15

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments70.04101.15142.82174.30104.7952.8645.3693.6042.95
Short Term Receivables0.000.000.003.24125.0025.0028.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.700.710.520.872.965.201.801.171.02
Total Current Assets70.74101.86143.35178.42232.7583.0675.1794.7743.97
Net Property, Plant & Equipment0.280.270.520.270.380.290.350.240.04
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets----0.100.060.05--
Other Assets1.042.484.462.610.000.000.000.090.17
Total Assets72.06104.61148.33181.29233.2383.4275.5795.0944.17
Short Term Debt Incl. Current Port. of LT Debt15.530.3015.391.160.233.890.230.000.12
Accounts Payable0.160.181.340.131.020.380.813.051.00
Other Current Liabilities12.1218.125.5414.0710.528.1311.875.422.24
Total Current Liabilities27.8118.6022.2615.3611.7712.4112.918.473.35
Long Term Debt0.0015.000.2714.9215.6311.4314.530.001.22
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities----0.100.060.05--
Other Liabilities0.000.006.000.000.000.000.000.000.00
Total Liabilities27.8133.6028.5330.2827.5023.9127.498.474.57
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity44.2571.00119.80151.01205.7459.5148.0886.6239.60
Total Shareholders Equity44.2571.00119.80151.01205.7459.5148.0886.6239.60
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity44.2571.00119.80151.01205.7459.5148.0886.6239.60
Total Liabilities & Stockholders Equity72.06104.61148.33181.29233.2383.4275.5795.0944.17
Book Value Per Share0.741.192.022.583.541.541.683.302.07
Tangible Book Value Per Share0.741.192.022.583.541.541.683.302.07
Full-Time Employees8910151211201912
Price to Book Ratio1.083.491.692.511.134.463.462.512.83
Return on Assets-38.32-44.16-22.78-29.93-36.49-47.24-71.28-55.85-64.42
Return on Equity-58.73-58.54-27.73-34.77-43.56-69.81-90.31-61.63-72.95
Return on Invested Capital-76.49-64.94-31.27-37.38-26.10-52.94-97.15-44.90-54.73
Quick Ratio2.545.486.4411.6219.776.695.8211.1813.11
Current Ratio2.545.486.4411.6219.776.695.8211.1813.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-19.13-33.85-55.85-37.54-62.02-57.78-37.55-60.83-38.89
Depreciation0.360.250.250.260.260.260.060.100.07
Other Funds (Non Cash)2.925.436.486.098.577.529.3114.323.97
Funds from Operations-15.85-28.17-49.12-31.19-53.19-49.99-28.66-47.73-34.86
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.27-5.185.910.86-3.447.44-8.832.745.00
Cash from Operating Activities-19.12-33.35-43.21-30.33-56.64-42.56-37.49-44.98-29.86
Capital Expenditures-0.020.000.000.00-0.02-0.010.00-0.01-0.26
Net Assets From Acquisitions0.000.000.000.000.000.000.000.61-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments16.0047.74-44.9230.00-29.940.0029.0217.88-23.07
Purchase of Investments0.00-40.26-96.920.00-92.940.00-5.78-57.77-59.73
Sale Or Maturity of Investments16.0088.0052.0030.0063.000.0034.8075.6436.66
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities15.9847.74-44.9230.00-29.95-0.0129.0218.48-23.34
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.081.120.120.311.22194.5041.909.2581.92
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.081.120.120.311.22194.5041.909.2581.92
Proceedsfrom Stock Options0.000.00-0.270.000.00189.8140.727.8981.84
Issuance or Reduction of Debt, Net-15.300.00-0.29-1.040.000.000.0014.330.00
Change in Long Term Debt-15.300.000.000.000.000.000.0014.330.00
Issuance of Long Term Debt0.000.000.000.000.000.000.0014.330.00
Reduction of Long Term Debt-15.300.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.530.000.000.000.00-1.40
Other Financing Activities Uses0.000.000.00-0.530.000.000.000.00-1.40
Cash from Financing Activities-15.221.12-0.17-1.271.22194.5041.9023.5880.53
Net Change in Cash-18.3715.51-88.30-1.60-85.37151.9333.43-2.9327.33
Free Cash Flow-19.15-33.35-43.21-30.33-56.65-42.56-37.49-44.99-30.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00-0.48-1.310.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments40.9745.0965.0070.0475.3081.92
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.331.660.380.701.031.22
Total Current Assets42.3046.7565.3870.7476.3383.14
Net Property, Plant & Equipment0.460.160.210.280.340.40
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.620.630.901.041.131.42
Total Assets43.3847.5466.4872.0677.8084.96
Short Term Debt Incl. Current Port. of LT Debt0.180.1415.5115.5315.4715.41
Accounts Payable0.140.140.140.160.011.46
Other Current Liabilities7.569.378.6712.1213.0012.66
Total Current Liabilities7.889.6624.3327.8128.4829.53
Long Term Debt0.280.000.000.000.070.14
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities8.169.6624.3327.8128.5629.67
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity35.2237.8942.1644.2549.2455.29
Total Shareholders Equity35.2237.8942.1644.2549.2455.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity35.2237.8942.1644.2549.2455.29
Total Liabilities & Stockholders Equity43.3847.5466.4872.0677.8084.96
Book Value Per Share0.580.630.700.740.820.92
Tangible Book Value Per Share0.580.630.700.740.820.92
Full-Time Employees-67888
Price to Book Ratio1.083.052.306.335.673.62
Return on Assets-31.57-34.80-34.28-38.32-44.27-47.98
Return on Equity-45.29-49.48-51.76-58.73-64.31-65.91
Return on Invested Capital-10.60-14.39-8.19-14.60-15.59-17.62
Quick Ratio5.374.842.692.542.682.82
Current Ratio5.374.842.692.542.682.82

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-3.76-5.45-3.45-6.46-7.69-9.77
Depreciation0.150.070.070.070.060.06
Other Funds (Non Cash)1.111.64-0.941.102.36-0.18
Funds from Operations-2.49-3.74-4.32-5.30-5.26-9.89
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.63-0.85-0.790.00-1.761.33
Cash from Operating Activities-4.12-4.59-5.11-5.30-7.02-8.56
Capital Expenditures0.00-0.020.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.0016.0025.00-0.55
Purchase of Investments0.000.000.000.000.00-24.55
Sale Or Maturity of Investments0.000.000.0016.0025.0024.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.020.0016.0025.00-0.55
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.000.070.000.120.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.000.070.000.120.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-15.300.000.000.000.00
Change in Long Term Debt0.00-15.300.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-15.300.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.01-15.300.070.000.120.00
Net Change in Cash-4.11-19.91-5.0410.7018.10-9.11
Free Cash Flow-4.12-4.61-5.11-5.30-7.02-8.56

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.44%3.2M58.1M1.15M
2026-10-155.48%3.2M58.1M1.19M
2026-09-305.97%3.5M58.1M1.07M
2026-09-156.20%3.6M58.1M1.25M
2026-08-315.37%3.1M58.1M1.30M
2026-08-145.72%3.3M58.1M1.36M
2026-07-315.89%3.4M58.1M1.36M
2026-07-156.19%3.6M58.1M1.37M
2026-06-309.77%5.7M58.1M1.43M
2026-06-1511.82%6.9M58.1M2.96M
2026-05-2913.61%8.0M58.4M3.08M
2026-05-1512.98%7.6M58.4M3.06M
2026-04-3013.19%7.4M55.8M3.06M
2026-04-159.97%5.5M55.6M3.05M
2026-03-319.86%5.5M55.7M2.83M
2026-03-1311.55%6.4M55.7M1.14M
2026-02-279.44%5.3M55.7M1.06M
2026-02-139.84%5.5M55.7M1.05M
2026-01-309.02%5.3M58.2M1.04M
2026-01-158.76%5.1M58.2M990.84K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.200.123.57010.000.000.769-0.0050.000
call1.000.000.050.053.41549.000.000.293-0.0060.000
call1.500.000.200.184.8092.000.000.240-0.0080.000
call2.000.000.050.055.6764110.000.219-0.0090.000
call3.000.000.050.006.7870.000.000.199-0.0100.000
call4.000.001.000.007.8570.000.000.188-0.0120.000
put0.500.000.050.002.8080.000.00-0.231-0.0040.000
put1.000.000.750.5012.7321,0010.00-0.707-0.0070.000
put1.500.501.450.9724.9072.000.00-0.760-0.0080.000
put2.001.001.951.4325.6732.000.00-0.781-0.0090.000
put3.002.002.952.4526.7364.000.00-0.801-0.0110.000
put4.002.903.903.5523.5613.000.00-0.816-0.0110.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-06SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-08-12SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-28SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-158-KCurrent report2026-07-14SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-113Initial statement of beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-018-KCurrent report2026-05-01SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-06-10SEC
2026-04-208-KCurrent report2026-04-20SEC
2026-04-018-KCurrent report2026-04-01SEC
2026-03-314Statement of changes in beneficial ownership of securities2026-03-27SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06418.45K100
2026-050000
2026-040000
2026-03105.10K200
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Knoll Capital Management, LLC9.08%
AQR CAPITAL MANAGEMENT LLC6.22%
KINGDON CAPITAL MANAGEMENT, L.L.C.4.40%
ACADIAN ASSET MANAGEMENT LLC3.97%
VANGUARD CAPITAL MANAGEMENT LLC3.92%
D. E. Shaw & Co., Inc.3.22%
MARSHALL WACE, LLP2.50%
683 Capital Management, LLC2.40%
JANE STREET GROUP, LLC2.28%
BlackRock, Inc.2.08%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.96%
Fidelity Small Cap Index Fund0.90%
VANGUARD EXTENDED MARKET INDEX FUND0.86%
VANGUARD EXPLORER FUND0.55%
SMALL COMPANY GROWTH PORTFOLIO0.51%
VANGUARD RUSSELL 2000 INDEX FUND0.46%
Fidelity Extended Market Index Fund0.46%
iShares Micro-Cap ETF0.31%
VANGUARD HEALTH CARE INDEX FUND0.28%
U.S. MICRO CAP PORTFOLIO0.23%

OakChart. ALDX. Cached 15 minutes.